top of page


4 Feb 2023

Important results from the Horizon 2020 PREPARE study on pharmacogenetic-guided drug treatment using a 12-gene pharmacogenetic panel

Volume 401, Issue 10374 of The Lancet features an article titled 'A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study'.

The study shows significantly reduced (30%) incidence of clinically relevant adverse drug reactions when a DNA passport for medication is available upfront of treatment and proved feasibility to implement across diverse European health-care systems.

Read the article.

bottom of page